ovarian cancer (oc) is the most deadly gynaecological cancer. despite surgery and first-line chemotherapy, between 60 % and 70 % of oc patients will recur with poor prognosis. Several studies suggest anti-tumour activity of tumour necrosis factor (TNF) when given systematically, but the high toxicity of the drug has limited its use. NGR-human TNF (hTNF) consists of TNF coupled with the peptide NGR that selectively binds to cd13, which is overexpressed on tumour blood vessels. NGR-hTNF is able to increase the intratumoural doxorubicin distribution by altering tumour vasculature. The activity and toxicity profile of NGR-hTNF-doxorubicin combination in recurrent oc will be described.
was 42,700 with a mortality of 12/100,000 women/year. 2 The current treatment of oc involves aggressive cytoreductive surgery followed by platinum-and taxane-based chemotherapy, which produces an objective response rate in approximately 65-80% of patients. 3 Nevertheless, despite surgery and first-line chemotherapy, between 60 % and 70 % of oc patients will recur and their prognosis and quality of life remain poor. 4 Platinum-based combination therapies represent the standard care for patients recurring more than six months after initial therapy; 5 combination treatment with paclitaxel and gemcitabine have been reported to increase outcome in terms of platinum monotherapy in recurrent platinum-sensitive patients. 6 Recently, the aarboplatin and Pegylated liposomal doxorubicin [Pld] versus carboplatin and Paclitaxel in Relapsed Platinum-sensitive ovarian cancer (calYPSo) trial reported a better therapeutic index for the combination of carboplatin-Pld in comparison with carboplatinpaclitaxel in recurrent, platinum-sensitive oc thus representing, for most clinicians, the preferred option in this setting.
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The response to platinum retreatment is related to the length of prior response to platinum. 8, 9 it has been postulated that patients with partially platinum-sensitive recurrent oc (platinum-free interval [PFi] between six to 12 months) may benefit from a strategy of artificially extending the PFi by using a non-platinum agent followed by platinum at subsequent relapse. 10 in this view, after the publication of an Efficacy in general, platinum-resistant patients (who are patients recurring less than six months from last platinum treatment) are treated with sequential single non-platinum agents rather than with combination therapy 4 and, currently, the drugs approved in this subset of patients are paclitaxel, Pld, etoposide and topotecan with a short-lasting response rate in 10-25% of patients and a general dismal prognosis. 8, 9 Therefore, novel treatment strategies are required to improve outcomes in women with recurrent oc, particularly in resistant disease.
Human NGR-Tumour Necrosis Factor
Tumour necrosis factor (TNF) was first identified by carswell et al. in the serum of Bacillus calmette-Guerin-sensitised animals treated with an endotoxin causing the release of a factor able to induce haemorrhagic necrosis of murine tumours. 12 in an in vitro experiment TNF has been shown to have cytostatic and cytotoxic effects against a wide range of human tumour cells and human tumour xenografts in nude mice. 13, 14 in addition to the well-known cytostatic/cytotoxic properties, TNF has a broad spectrum of immunomodulatory activities. 15 the anticancer activity of ngr-htnF was investigated in a preclinical series of experiments aimed at demonstrating the ability of the cytokine in inducing regression of neoplastic lesions both as single agent and in combination with chemotherapeutic drugs. preclinical anti-tumour activity studies showed that murine ngrtnF (ngr-mtnF) is almost 12 to 15 times more effective than mtnF in suppressing growth of rma-t and rma lymphoma and B16F1 melanoma in mice with similar toxicity. 23 a similar potency differential was observed between ngr-htnF and htnF against rma-t tumours in mice, thus a similar effect would be expected for ngr-htnF in man offering a better risk-benefit in cancer treatment.
the pharmacokinetic properties were investigated for both ngr-tnF and tnF and the dose-response curve, obtained for ngr-tnF was compared with similar amounts of tnF (at doses of 0.01, 1, 10, 100, 1,000 and 10,000 ng). In this experimental model, doses included between 0.01 to 1 ng/mouse of ngr-htnF (considered low doses) were sufficient to induce maximal effect, defined as tumour shrinkage; by contrast, in this experimental model, tnF was active only at high doses (1,000 and 10,000 ng/mouse). 
NGR-Human Tumour Necrosis FactorDoxorubicin Combination
anthracyclines are among the most used chemotherapy agents in several solid and haematological tumours: anthracyclines exert claimed anti-tumour activity in oc; nevertheless, the effect on survival was demonstrated only in isolated clinical trials. 35 In fact, in most studies the addition of doxorubicin had no effect on survival -only affecting the safety profile of the treatment especially in terms of myelotoxicity -and some authors reported that this could be related to the poor penetration of doxorubicin into cancer cells. enhancing tumour cell penetration of the drug without changing the pharmacokinetics and/or increasing the toxicity profile of doxorubicin. In mouse models bearing WEHI-164 fibrosarcoma cells treated with 0.1 ng/ mouse of ngr-mtnF followed by the administration of doxorubicin, the maximal synergism between drugs was observed when doxorubicin was administered two hours after the infusion of ngr-mtnF. after a median follow up of 14.6 months, the one-year survival rate was 65%; median survival was 24.0 months in patients with pr or SD and 4.9 months in patients with progression of disease (p<0.0001) (see Figure 1 ).
Interestingly, a correlation was documented between basal peripheral blood lymphocyte count (pBlc) and outcome: in the subset of refractory/resistant patients with pBlc higher or lower than 1.2/ml (i.e. the 25th percentile distribution value) a median pFS of 4.9 and 2.6 months (p=0.02) and a median oS of 15.8 and 4.3 months (p=0.0001), respectively, were registered (see Figure 2) . In univariate cox analyses, both longer pFI (p=0.03) and higher baseline pBlc (p=0.01) were significantly associated with better pFS, and only overall survival correlated with pBlc (p=0.001).
chemotherapy treatment appeared well tolerated: most common grade 3 non-haematological aE were asthenia (3 % of patients); two patients (5 %) reported grade 1 cardiac aE (one tachycardia and one diastolic dysfunction). only 9 % of all recorded aEs were related to ngr-htnF infusion and were generally represented by short-lived, infusion-related, grade 1 to 2 chills (65 % of patients). In terms of haematological toxicity, grade 3 and 4 neutropoenia were registered in seven (19 %) and 16 patients (43 %), respectively, with grade 3 and 4 anaemia in nine (24 %) and one patient (3 %), respectively. only one episode of neutropenic fever was reported (3 %). all cycles were given at the planned dose, except for eight patients (22 %) in which a doxorubicin dose reduction was required.
We concluded that ngr-htnF-doxorubicin combination retains interesting clinical activity and a secure toxicity profile in recurrent oc.
the evidence of disease control achieved in more than half of patients and maintained for a median of more than six months is of note particularly in the resistant recurrent setting; moreover, in our study a low lymphocyte count at baseline seems to predict early progression and short survival, whereas a normal lymphocyte count seems to correlate with prolonged clinical benefit. these clinical observations are consistent with preclinical evidence of a synergism between ngrhtnF and doxorubicin, reported only in immunocompetent mice, being lacking in nude mice depleted of functionally mature t lymphocytes. 39 From this viewpoint, the baseline pBlc could be an easily accessible and reproducible predictive biomarker of outcome, which might be exploited for selecting refractory/resistant oc patients who would mostly benefit from the combination of ngr-htnF and doxorubicin (see Figure 2 ). toxicity profiles of the two drugs apparently did not overlap; most common aEs are those expected when each agent is given alone, consisting of neutropoenia for doxorubicin and chills for ngr-htnF. more interestingly, cardiovascular toxicities previously reported for vascular targeting agents 40 did not appear in our study and, even more importantly, despite half of patients completing six or more cycles of doxorubicin, there was no exacerbation of the well-known cardiac toxicity profile of doxorubicin.
given the outstanding use of plD in oc and the synergism documented in preclinical models between low-dose tnF and liposomal formulation of doxorubicin, 41 a randomised phase II trial (nct01358071) trial testing plD with or without ngr-htnF in recurrent, platinum-refractory/resistant oc is ongoing in several Italian institutions. n
